Source comparison
MK-677 Dosing, Recovery, and Research Protocol Comparison
10mg daily 40–50% Moderate sleep quality improvement, minimal appetite surge Low. Rare glucose elevation Initial research protocols, older populations 25mg daily 60–90% Significant IGF-1 elevation, marked sleep architecture improvement, accelerated nitrogen re
This comparison does not assign a generated winner or score.
- 10mg daily
- 40–50%
- Moderate sleep quality improvement, minimal appetite surge
- Low. Rare glucose elevation
- Initial research protocols, older populations
- 25mg daily
- 60–90%
- Significant IGF-1 elevation, marked sleep architecture improvement, accelerated nitrogen retention
- Moderate. Appetite surge 90 min post-dose, possible mild water retention
- Standard research dose for recovery studies, training-adapted populations
- 50mg daily
- 70–100%
- No additional IGF-1benefit vs 25mg
- High. Fasting glucose elevation in 30% of subjects, pronounced edema
- Rarely justified. Side effects outweigh marginal gains
- Evening timing
- N/A
- Aligns GH pulse with slow-wave sleep, appetite surge during final meal window
- Improved tolerability vs morning dosing
- Preferred for recovery-focused protocols
- Professional Assessment
- 25mg daily dosed in the evening is the most evidence-supported protocol. Higher doses don't meaningfully improve outcomes and lower doses underperform in training-adapted populations.